OPAL data is a gem! Large Australian data studying JAKi use in #rheumatoidarthritis N=5900 Switching JAKi~JAKi-common. As in TNFi 1st line Rx had longer retention & better efficacy than 2nd & subsequent. Median 1st advanced Rx - same in all JAKs 34 MOA @RheumNow #ACR22 abst0274 https://t.co/FQU4AKXwe9

Dey @DrMiniDey @ElenaNikiUK @docrota @LatikaGupta_ et al. COVID vaccination in IIM+multimorbidity. Adverse events more common, but still infrequent. Both multimorbidity and active IIM increased risk of AEs. @rheumnow #ACR22 Abstr#0177 https://t.co/HA5NaRrPYL https://t.co/TKtagwa0gG

• COVID-19 Vaccination-related Short-term Adverse Events in Patients with Idiopat…

Coming soon on #ACR22: Stream session 12S119 on @ACRheum and @ACRheumDC advocacy What is new on the Hill? What are ACR priorities How quickly can you send an email supporting rheumatologists (quicker than you think!) @RheumNow @AngusWorthing @BlairSolowM @LennMcD @LouisaZiglar https://t.co/sXSBGbCZyM

Froehlich et al. MRI superior to US in GCA. For all GCA sensitivity 73% vs 45%. For supra-aortic GCA sensitivity 73% vs 59%. Both 100% specificity. @rheumnow #ACR22 Abstr#0493 https://t.co/vf2r0h5zUd https://t.co/mlSCcpy2uK

• MRI Is Superior to Ultrasound of Supraaortic Arteries in Detecting Giant Cell A…

Very complex conversation on why opioids are used... Opioid use in patients with PsA and AS led to higher healthcare utilization and higher costs. Opioid users - more co-morbidities, smokers, worse disease activity Opioid users spent more on drug costs Abs#0402 @RheumNow #ACR22 https://t.co/dbUPg5LGLy

Rathmann et al. Incidence/Prevalence AAV in Sweden over time. Incidence stable. Prevalence increasing and higher in men. Incidence increases with age and commonest 70-84 years @rheumnow #ACR22 Abstr#0451 https://t.co/yCMOC7dAvq https://t.co/y0tqkaV8zX

• Incidence and Prevalence of ANCA-associated Vasculitis in Southern Sweden – a 2…

#ACR22 Abstr#2081 What is the nature of breakthrough #COVID infection in #lupus patients in Omicron era? A cohort study in New York showed those receiving booster vac were less likely to develop infection vs receiving 2 vaccine doses. Only 2 hospitalised, no deaths @RheumNow https://t.co/6UaTMN5Dev

Rooney et al. Seasonality of GCA in UK and Ireland - DCVAS/TABUL/local hospital combined dataset. 2 peaks - spring/early summer every year, and a second peak most years in autumn or winter. @rheumnow #ACR22 Abstr#0495 https://t.co/Trz8ou9xGh https://t.co/jcS3Z30nz8

• Seasonal Variation in the Incidence of GCA in the UK and Ireland - ACR Meeting …

Do you see #JAKis causing weight gain? 429 Pts BUT during #COVID19 - 68% gained wt in RA 1.5 Kg mean; and more in SpA 71% w 2.6 Kg. Was it Rx or COVID related? #ACR22 abst0291 @RheumNow

Ruiz et al. bDMARD/tsDMARD use in RA after breast cancer. Low use, 15.5% on bDMARD, 1.5% on tsDMARD. Stable use over last 10 years @rheumnow #ACR22 Abstr#0080 https://t.co/0L6uuVtQQw https://t.co/xBH1bUdeSD

• Utilization of Biologic and Targeted Disease Modifying Antirheumatic Therapy in…

#disparities study using admin data - 580 pts with incidence childhood #SLE with LN - LN codes before SLE codes - more likely publicly insured, rural area, Hispanic ethnicity, kidney transplant - differential access!! @RADoctor @rheumnow #ACR22 abst#0068 https://t.co/uryCZq94dX

Early Izokibep (IL17Ai) data demonstrated clinically meaningful, dose-dependent improvement across PROs, particularly sleep, pain, function ,+ SF36 and PsAID subdomains in PsA pts. Pts w/ baseline enthesitis had greater benefit. Abs 0199 #ACR22 @RheumNow https://t.co/sXVdwGPVnd https://t.co/Cxyfp6OXOY

• Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes - 16-Wee…

Did you get the updated #COVIDbooster before you arrived at #ACR22? Answers are anonymous @rheumnow

Use of AI to detect sacroilitis in axSpA and nr-axSpA. Pre-trained AI neural network can detect sacroilitis, especially new data, similar to human radiology experts. Abs#0383 @RheumNow #ACR22 https://t.co/5hdrKxT3HP